<DOC>
	<DOCNO>NCT01565109</DOCNO>
	<brief_summary>It estimate 7300 number new case gastric cancer year France . According randomized trial compare 3 cycle ECF ( epirubicin , cisplatin , 5FU ) administer surgery 3 cycle surgery surgery alone adenocarcinoma stomach low esophagus , clinical experimental data neoadjuvant chemotherapy new standard treatment operable gastric cancer . This treatment median survival 3 year obtain hazard ratio 0.75 favor chemotherapy arm ( p = 0.009 ) . The 5-year survival 36 % patient treat chemotherapy versus 23 % surgery alone . Progression-free survival also significantly prolong hazard ratio 0.66 . The propose clinical study Ajani et al show combination Docetaxel schema Cisplatin - 5FU provide great clinical benefit induces consider triple combination reference treatment metastatic gastric cancer patient 65 year . Preoperative radiochemotherapy expect increase rate curative resection , reduce gastrointestinal hematologic toxicity . Two study evaluate feasibility preoperative RTCT operable gastric adenocarcinoma continuous 5GU ( + - paclitaxel ) 45 Gy available combination 5FU oxaliplatin assess esophagus rectum tumor . The NESC study , Phase II , propose follow schema : 2 cycle chemotherapy Docetaxel - Cisplatin - 5FU preoperative chemoradiation oxaliplatin - continuous 5FU radiotherapy locally advance gastric adenocarcinoma stage III IV non-metastatic administer surgery .</brief_summary>
	<brief_title>NESC : Neoadjuvant Treatment Of Gastric Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Male female patient , Age : 18 65 ECOG performance status ≤ 1 Histological documentation gastric adenocarcinoma . An extension admit omentum Adenocarcinoma stomach accord stag classification TNM Scannographic : T2bN0 , T2bN1 , T3NO T3N + , T4N0 , T4N + M0 ( cardia , Siewert II , III , fundus , body , antrum ) perform ultrasonography CT Scan . Optional : laparoscopy A positive peritoneal cytology disqualify factor macroscopic carcinomatosis Absence previous abdominal irradiation 5th sacral vertebra ( liver , pancreas , spleen , mediastinal lodge ) Loss weight le 15 % base weight diagnosis No psychological , familial , sociological geographical condition may affect compliance adherence treatment , patient monitoring understanding study . Signed informed consent obtain study specific procedure . Food Consumption &gt; 1000 calorie / day whatever mode administration ( enteral parenteral ) Laboratory test conduct within one week start study treatment : Absolute neutrophil count &gt; 1500/mm3 Platelet count &gt; 100 000/mm3 Total bilirubin &lt; 2 mg/dL Serum creatinine &lt; 13 mg/dL creatinine clearance &gt; 40 ml/min Hemoglobin ( Hgb ) ≥ 10 g/dL ( Hemoglobin transfusion necessary ) ALT / AST &lt; 1.5 x ULN PTT ≥ 60 % Life expectancy least 3 month Peripheral sensory neuropathy ≥ grade 1 ( accord CTCAE version 3.0 ) . Myocardial infarction , stroke pulmonary embolism , unstable angina le 6 month start study drug . Uncontrolled infection Pregnant breastfeeding patient . Women childbearing potential must pregnancy test performed . Prior treatment gastric adenocarcinoma Lower limbs arteritis ( ≥ stage II accord Leriche Fontain classification ) Patient participate another clinical trial already receive anticancer treatment Concomitant treatment phenytoin Known previous / current malignancy within last 5 year except nonmelanoma skin , nonmetastatic prostate carcinoma cervival carcinoma situ superficial bladder carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>NESC</keyword>
	<keyword>NEOADJUVANT</keyword>
	<keyword>GASTRIC</keyword>
</DOC>